Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 431

1.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
[PubMed - indexed for MEDLINE]
2.

A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M.

J Sex Med. 2012 Jun;9(6):1624-33. doi: 10.1111/j.1743-6109.2012.02718.x. Epub 2012 Apr 17.

PMID:
22510238
[PubMed - indexed for MEDLINE]
3.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.

Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Review.

PMID:
21726934
[PubMed - indexed for MEDLINE]
4.

Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.

Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C.

Eur Urol. 2011 Sep;60(3):527-35. doi: 10.1016/j.eururo.2011.05.054. Epub 2011 Jun 12. Review.

PMID:
21684677
[PubMed - indexed for MEDLINE]
5.

Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.

Miller MS.

Ann Pharmacother. 2013 Feb;47(2):278-83. doi: 10.1345/aph.1R528. Epub 2013 Feb 5. Review.

PMID:
23386068
[PubMed - indexed for MEDLINE]
6.
7.

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.

Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20.

PMID:
22297243
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team.

Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005. Epub 2011 Aug 12.

PMID:
21871706
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.

Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E.

J Sex Med. 2009 Feb;6(2):544-52. doi: 10.1111/j.1743-6109.2008.01109.x. Epub 2008 Dec 2.

PMID:
19138360
[PubMed - indexed for MEDLINE]
10.

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E.

Eur Urol. 2008 Jun;53(6):1236-44. doi: 10.1016/j.eururo.2008.01.075. Epub 2008 Feb 4.

PMID:
18281145
[PubMed - indexed for MEDLINE]
11.

Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.

Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, Choi HY, Park HY, Lee SW.

J Androl. 2012 May-Jun;33(3):397-403. doi: 10.2164/jandrol.111.013185. Epub 2011 Aug 25.

PMID:
21868753
[PubMed - indexed for MEDLINE]
Free Article
12.

[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].

Herlemann A, Gratzke C, Andersson KE, Sievert KD.

Urologe A. 2013 Feb;52(2):204-11. doi: 10.1007/s00120-012-3084-2. Review. German.

PMID:
23417046
[PubMed - indexed for MEDLINE]
13.

Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.

Brock GB, McVary KT, Roehrborn CG, Watts S, Ni X, Viktrup L, Wong DG, Donatucci C.

J Urol. 2014 Feb;191(2):405-11. doi: 10.1016/j.juro.2013.09.057. Epub 2013 Oct 1.

PMID:
24096120
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.

Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.

Urology. 2013 Sep;82(3):667-73. doi: 10.1016/j.urology.2013.05.005. Epub 2013 Jul 19. Erratum in: Urology. 2014 Mar;83(3):684.

PMID:
23876588
[PubMed - indexed for MEDLINE]
15.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ.

J Sex Med. 2012 Jan;9(1):271-81. doi: 10.1111/j.1743-6109.2011.02504.x. Epub 2011 Oct 7.

PMID:
21981682
[PubMed - indexed for MEDLINE]
16.

[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].

Giuliano F, Rouprêt M, Doridot G, de la Taille A.

Prog Urol. 2013 Apr;23(5):283-95. doi: 10.1016/j.purol.2012.11.009. Epub 2012 Dec 28. Review. French.

PMID:
23545003
[PubMed - indexed for MEDLINE]
17.

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.

Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M.

Prostate. 2013 Sep;73(13):1391-402. doi: 10.1002/pros.22686. Epub 2013 Jun 13.

PMID:
23765639
[PubMed - indexed for MEDLINE]
18.

Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

Kaplan SA, Gonzalez RR, Te AE.

Eur Urol. 2007 Jun;51(6):1717-23. Epub 2007 Jan 16. Erratum in: Eur Urol. 2008 Jun;53(6):1320.

PMID:
17258855
[PubMed - indexed for MEDLINE]
19.
20.

Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.

Wang C.

Curr Opin Urol. 2010 Jan;20(1):49-54. doi: 10.1097/MOU.0b013e328333ac68. Review.

PMID:
19887943
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk